Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
My Dad Can't Travel Like He Used to, but Slowing Down Doesn't Mean Stopping - 2'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- 3Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- 4In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 5This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- Three killed as unfinished building collapses on church service in Ghana
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- Remote Headphones: Upgrade Your Sound Insight
- Vote in favor of your Number one method for commending a birthday
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Top 15 Web-based Entertainment Stages for Individual Marking
